Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/77560
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rodriguez Abreu, D. | en_US |
| dc.contributor.author | Garassino, M.C. | en_US |
| dc.contributor.author | Esteban, E. | en_US |
| dc.contributor.author | Speranza, G. | en_US |
| dc.contributor.author | Felip, E. | en_US |
| dc.contributor.author | Domine, M. | en_US |
| dc.contributor.author | Hochmair, M.J. | en_US |
| dc.contributor.author | Powell, S.F. | en_US |
| dc.contributor.author | Cheng, S.Y.-S. | en_US |
| dc.contributor.author | Bischoff, H. | en_US |
| dc.contributor.author | Peled, N. | en_US |
| dc.contributor.author | Hui, R. | en_US |
| dc.contributor.author | Reck, M. | en_US |
| dc.contributor.author | Garon, E.B. | en_US |
| dc.contributor.author | Boyer, M. | en_US |
| dc.contributor.author | Grossi, F. | en_US |
| dc.contributor.author | Jennens, R. | en_US |
| dc.contributor.author | Yang, J. | en_US |
| dc.contributor.author | Pietanza, M.C. | en_US |
| dc.contributor.author | Gadgeel, S.M. | en_US |
| dc.date.accessioned | 2021-02-05T14:39:18Z | - |
| dc.date.available | 2021-02-05T14:39:18Z | - |
| dc.date.issued | 2018 | en_US |
| dc.identifier.issn | 0923-7534 | en_US |
| dc.identifier.uri | http://hdl.handle.net/10553/77560 | - |
| dc.description.abstract | In KEYNOTE-189 (NCT02578680), pembro plus pem and platinum provided superior OS (HR 0.49, P < .00001) and PFS (HR 0.52, P < .00001) and had manageable safety vs placebo plus pem and platinum as first-line therapy for metastatic nonsquamous NSCLC. In an exploratory analysis, we assessed outcomes by investigator’s choice of carboplatin (carbo) or cisplatin (cis). | en_US |
| dc.language | eng | en_US |
| dc.relation.ispartof | Annals of Oncology | en_US |
| dc.source | Annals of Oncology [0923-7534], n. 29 (supl. 8) | en_US |
| dc.subject | 320101 Oncología | en_US |
| dc.title | 1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? | en_US |
| dc.type | info:eu-repo/semantics/conferenceObject | en_US |
| dc.type | ConferenceObject | en_US |
| dc.relation.conference | European-Society-for-Medical-Oncology Asia Congress | en_US |
| dc.identifier.doi | 10.1093/annonc/mdy292.086 | en_US |
| dc.investigacion | Ciencias de la Salud | en_US |
| dc.type2 | Póster de congresos | en_US |
| dc.utils.revision | Sí | en_US |
| dc.identifier.ulpgc | Sí | en_US |
| dc.contributor.buulpgc | BU-MED | en_US |
| dc.description.sjr | 6,047 | |
| dc.description.jcr | 14,196 | |
| dc.description.sjrq | Q1 | |
| dc.description.jcrq | Q1 | |
| dc.description.scie | SCIE | |
| item.grantfulltext | none | - |
| item.fulltext | Sin texto completo | - |
| crisitem.event.eventsstartdate | 23-11-2018 | - |
| crisitem.event.eventsenddate | 25-11-2018 | - |
| Appears in Collections: | Actas de congresos | |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.